Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Biotech
ESMO: Boehringer builds case for late-phase rival to Imdelltra
Boehringer Ingelheim has shared data on its DLL3xCD3 T-cell engager, providing pointers to the prospects of a would-be rival to Amgen’s Imdelltra.
Nick Paul Taylor
Oct 23, 2026 10:30am
Vir CEO sees chance ‘to do more deals’ after $1.9B Gilead pact
Oct 14, 2026 8:30am
Novartis pens $7.8B deal for Abogen's in vivo autoimmune TCE
Oct 2, 2026 4:24am
Henlius carves out $440M T-cell engager deal with Amberstone
Sep 24, 2026 10:02am
GSK doubles down on Chimagen with $750M multiple myeloma wager
Sep 15, 2026 7:15am
AbbVie bispecific shows promise in ph. 3 multiple myeloma trial
Sep 3, 2026 9:20am
